Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial evaluating CBI 1214

Trial Profile

Clinical trial evaluating CBI 1214

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CBI 1214 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 10 Nov 2025 New trial record
  • 02 Oct 2025 According to Cartography Biosciences media release, CBI 1214 is on track for an investigational new drug application later this year and will initiate trial enrollment in early 2026.
  • 02 Oct 2025 According to Cartography Biosciences media release, company secured $US 67 million in a series B financing. company intends to utilise the funds to support the advancement of CBI 1214 into the clinic.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top